Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H7NO |
Molecular Weight | 109.1259 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC1=CN=CC=C1
InChI
InChIKey=MVQVNTPHUGQQHK-UHFFFAOYSA-N
InChI=1S/C6H7NO/c8-5-6-2-1-3-7-4-6/h1-4,8H,5H2
Nicotinyl alcohol is a direct-acting vasolidator, that may decrease the blood pressure and it is a cholesterol-lowering agent. Nicotinyl alcohol as a tartrate salt led to the efficiency improvements in patients with intermittent claudication. In addition, nicotinyl alcohol alone or associated with other drugs was studied in the treatment of radicular syndromes; and was shown, that the effect had not been due to mechanical compression.
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Other AEs: Increased appetite, Skin rash... Other AEs: Increased appetite (15%) Sources: Skin rash (36%) Itching (37%) Flushing (68%) Nausea (50%) Abdominal pain (15%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 15% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Increased appetite | 15% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Skin rash | 36% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Itching | 37% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Nausea | 50% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Flushing | 68% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Picolinyl ester fragmentation mechanism studies with application to the identification of acylcarnitine acyl groups following transesterification. | 2006 Nov |
|
Enzymatic oxidation of NADP+ to its 4-oxo derivative is a side-reaction displayed only by the adrenodoxin reductase type of ferredoxin-NADP+ reductases. | 2007 Aug |
|
Copper (II) complexes of the anti-inflammatory drug naproxen and 3-pyridylmethanol as auxiliary ligand. Characterization, superoxide dismutase and catecholase--mimetic activities. | 2010 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13383231
25 mg tablet 4 times a daily
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C10AD05
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
||
|
WHO-ATC |
C04AC02
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
||
|
WHO-VATC |
QC04AC02
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
||
|
WHO-VATC |
QC10AD05
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
526046
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
45213
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
NICOTINYL ALCOHOL
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
9TF312056Y
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
7414
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | RxNorm | ||
|
m7882
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000079994
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
CHEMBL1235535
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
D009540
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
C61860
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
7510
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
100-55-0
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
DTXSID6023367
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
1921
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
SUB14650MIG
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
202-864-6
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY | |||
|
DB04145
Created by
admin on Fri Dec 15 15:22:11 GMT 2023 , Edited by admin on Fri Dec 15 15:22:11 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)